![From QSR to QMSR: Meeting FDA’s New Requirements From QSR to QMSR: Meeting FDA’s New Requirements](https://www.fdanews.com/ext/resources/Book-Covers-NEW/From-QSR-to-QMSR-500.png?height=200&t=1714569011&width=200)
Home » MedImmune Lands Fast Track Status for Flu Candidate
MedImmune Lands Fast Track Status for Flu Candidate
![](https://www.fdanews.com/ext/resources/test/Drug-Images4/KeytoSuccess.gif?t=1474505946&width=430)
March 14, 2016
AstraZeneca’s MedImmune unit has snagged fast track designation for MEDI8852, which is being assessed for treating patients hospitalized with Type A strain influenza.
The candidate is being evaluated in a Phase 1b/2a clinical trial investigating a single dose in combination with oseltamivir, and as a monotherapy in adult patients with confirmed acute, uncomplicated Type A influenza.
Upcoming Events
-
21Oct